This is a company that has never made a profit. In fact, it’s never made any money at all. On top of that, analysts expect its per-share losses to double by the end of 2022. Assuming Adagio manages to generate some revenues next year — the market consensus is a minuscule $151 million — it’s already trading at almost 20 times those sales. Why? Because COVID is here to stay … and the search for a response is moving into new areas … quickly.
Vax In The Saddle Again I leave for a week of vacation, and I come back to … this? COVID-19 cases...
Read More
May The Pfourth Be With You Great Ones, I don’t know if we officially have a winner in the...
Read More
(4-minute read) The new crop of mRNA vaccines is a testament to scientific achievement in health care. They’re part of a much larger trend that we’ve been monitoring for a while. Here’s how to profit…
Long Train Runnin’ Down around the corner, half a mile from here … see them tech gains run, and...
Read More
Research Analyst
Director of VIP Services
Chief Investment Strategist of Money & Markets
Editor of Alpha Investor
Editor of Strategic Fortunes and three elite services